Growth

Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.

As the planet heats up and sea levels rise, the need to reduce carbon emissions is becoming ever more urgent. The life sciences industry is just one of many that are looking to cut the carbon it produces.

A positive mindset can boost exercise motivation. Learn how mental shifts help you start—and stick with—a healthier fitness routine.

Christopher Anzalone is spearheading Arrowhead Pharmaceuticals' transformation from a development-focused to a commercial-stage biotech. The CEO touts an “almost plug and play” platform, a derisked development strategy and a busy pipeline with vast potential.

The overall R&D productivity of the 30 largest public biopharma companies has increased despite a challenging global environment for investment and growth. Will hype cycles impact this picture in coming years?

Meron Mathias is vice president of CSR and sustainability at Thermo Fisher, whose specialty diagnostics division makes it the fifth leading player by revenues in the global IVD industry. In this podcast, she reflects on Thermo Fisher’s early commitment to ESG and sustainability reporting, its Scope 1, 2 and 3 targets and how regulation is moving industry towards a mandatory disclosure landscape.

Meron Mathias is vice president of CSR and sustainability at Thermo Fisher, whose specialty diagnostics division makes it the fifth leading player by revenues in the global IVD industry. In this podcast, she reflects on Thermo Fisher’s early commitment to ESG and sustainability reporting, its Scope 1, 2 and 3 targets and how regulation is moving industry towards a mandatory disclosure landscape.

King’s College London has released a freely available ‘Human Gut Microbiome Atlas’ to help researchers better understand how microorganisms in the gut impact disease.

It has been quite a year for German biotech Tubulis, and CEO Dominik Schumacher tells In Vivo that the group has the potential to be “a really meaningful, sizable leader” in the antibody-drug conjugate space.

Taylor Wessing investment partners share their thoughts about market trends, the surge in AI interest and the new UK government’s approach to the life sciences agenda.

Taylor Wessing investment partners share their thoughts about market trends, the surge in AI interest and the new UK government’s approach to the life sciences agenda.

George Badescu, chief business officer at Heidelberg Pharma, discusses antibody-drug conjugate development, partnership styles and the appetite for risk-taking in the biopharma industry.

The recent Women in Advanced Therapies Global event, delivered via an interactive 24-hour platform, hosted a number of biopharma speakers who drew on personal and industry-wide experiences, all aligned by a desire to break biases.

An analysis of new ADCs in Phase III studies shows the difficulties, and possible rewards, of developing these drugs. The earlier stage pipeline boasts a range of mechanistic approaches.

An analysis of new ADCs in Phase III studies shows the difficulties, and possible rewards, of developing these drugs. The earlier stage pipeline boasts a range of mechanistic approaches.   

Ali Pashazadeh, CEO, chair and founder of Treehill Partners discusses the need for increased communication between biotech and biopharma. 

Biopharmaceutical venture capital fundraising is on the rise in 2024. In late June, Formation Bio secured a mega financing, raising $372m via a series D round led by a16z and Sanofi. 

Exec summary testing space - June 2024.

Key insights from the recent the BIO International Convention in San Diego, US.